Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients

被引：0
|
作者：
Thomas, M. K. [1 ]
Nikooienejad, A. [1 ]
Bray, R. [1 ]
Cui, X. [1 ]
Wilson, J. [1 ]
Duffin, K. [1 ]
Milicevic, Z. [2 ]
Haupt, A. [1 ]
Robins, D. A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Vienna, Austria
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
735
引用
收藏
页码：S354 / S354
页数：1
相关论文
共 50 条
  • [41] Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
    Wang, Lijing
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1547 - 1559
  • [42] Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes
    Mahase, Elisabeth
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 382 : 2074
  • [43] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    [J]. Cardiovascular Diabetology, 21
  • [44] GLP-1 agonist liraglutide improves insulin sensitivity
    Di Lellis, Maddalena Angela
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (03) : 172 - 172
  • [45] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [46] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [47] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    [J]. LANCET, 2021, 398 (10295): : 143 - 155
  • [48] Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES, 2019, 68
  • [49] The Dual GIP and GLP-1 Receptor Agonist Tirzepatide Regulates Lipid and Carbohydrate Metabolism through GIPR in Adipose Tissue
    Samms, Ricardo Justin
    Christe, Michael E.
    Ruan, Xiaoping
    Moyers, Julie
    Regmi, Ajit
    Roell, William C.
    [J]. DIABETES, 2019, 68
  • [50] Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
    Lee, Clare J.
    Mao, Huzhang
    Thieu, Vivian T.
    Lando, Laura Fernandez
    Thomas, Melissa K.
    [J]. JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (05)
12345